Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2016

View Archived Issues

Phase II results demonstrate safety and efficacy of new drug for Wilson's disease

Oyi-based therapeutic HIV vaccine reduces the HIV RNA rebound median following cART interruption

TGI and Quark enter discovery and development collaboration

Zavante starts ZEUS trial for ZTI-01 in cUTI patients

KU Leuven and Ortho-McNeil-Janssen Pharmaceuticals patent dengue viral replication inhibitors

Oncolytics reports results on Reolysin phase II study

Akari and XL-protein to develop longer-acting version of Coversin

Synta Pharmaceuticals and Madrigal Pharmaceuticals announce merger agreement

RespiVert and Topivert Pharma disclose MAPK14, Src and Syk inhibitors

Redx Pharma develops IDO1 and/or TDO2 inhibitors

XuanZhu Pharma describes ALK and MCF3 inhibitors

Merrimack and Leica partner to develop companion diagnostic assays

PI3K inhibitors revealed in XuanZhu Pharma patent

Presage extends alliance with Takeda to provide access to CIVO platform

Burzynski Research Institute initiates phase II trial in diffuse intrinsic brainstem glioma

GeoVax receives SBIR grant for clade B HIV vaccine

TGen announces two new combination trials in pancreatic cancer

FDA acepts sBLA for Opdivo in patients with classical Hodgkin lymphoma

PsiOxus and Parker Institute collaborate on T-sign cancer platform

USAID launches Combating Zika and Future Threats: A Grand Challenge for Development

Phase I/IIa study investigates topically applied bisphosphocin Nu-3 for diabetic ulcers

FBRI and Meiji Seika collaborate on autoimmune and cancer drug research

Promising HCV T-cell vaccine HCV-003 to advance to phase II trials

Novel mutation in USMG5 gene may cause Leigh syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.